Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open Label, Pilot Phase II Study to Evaluate the Feasibility and Efficacy of CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Next Previous
Trial Profile

An Open Label, Pilot Phase II Study to Evaluate the Feasibility and Efficacy of CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Status: Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 27 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Devimistat (Primary) ; Metformin (Primary)
  • Indications Acute myeloid leukaemia; Sarcoma
  • Focus Therapeutic Use
  • Sponsors Cornerstone Pharmaceuticals Inc

Most Recent Events

  • 19 Sep 2024 Status changed from not yet recruiting to withdrawn prior to enrolment.
  • 07 Aug 2024 Planned initiation date changed from 1 Jul 2024 to 1 Dec 2024.
  • 02 May 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Apr 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top